MEDA Pharma GmbH & Co. KG clinical trials
Acquired by Viatris Inc., Nov 16, 2020 · source ↗
The registry lists 24 studies whose lead sponsor is MEDA Pharma GmbH & Co. KG. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jan 9, 2026.
Before and after it joined Viatris Inc.
- First submitted before MEDA Pharma GmbH & Co. KG became part of Viatris Inc.
- 21
- First submitted after MEDA Pharma GmbH & Co. KG became part of Viatris Inc.
- 3
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- MEDA Pharma GmbH & Co. KG24 studies
Something wrong with this grouping? Tell us on the Viatris Inc. page.
Studies
Recruiting first, then most recently updated. Showing 24 of 24. All Viatris Inc. studies →
- Real-world Evidence Study on CystistatCompletedNCT05544695
Sponsor listed in the registry: MEDA Pharma GmbH & Co. KG · First submitted after MEDA Pharma GmbH & Co. KG became part of Viatris Inc.
- Azelastine Allergen Chamber - Onset of Action StudyCompletedNCT06126952Phase 2
Sponsor listed in the registry: MEDA Pharma GmbH & Co. KG · First submitted after MEDA Pharma GmbH & Co. KG became part of Viatris Inc.
- Dymista Allergen Chamber - Onset of Action StudyCompletedNCT04652245Phase 4
Sponsor listed in the registry: MEDA Pharma GmbH & Co. KG · First submitted after MEDA Pharma GmbH & Co. KG became part of Viatris Inc.
- MP-AzeFlu Allergen Chamber - Onset of Action StudyCompletedNCT03004131Phase 4
Sponsor listed in the registry: MEDA Pharma GmbH & Co. KG · First submitted before MEDA Pharma GmbH & Co. KG became part of Viatris Inc.
- DYmista NAsal Spray in CHInese PatientsCompletedNCT03599791Phase 3
Sponsor listed in the registry: MEDA Pharma GmbH & Co. KG · First submitted before MEDA Pharma GmbH & Co. KG became part of Viatris Inc.
- Aldara for the Treatment of Large and/or Multiple sBCCCompletedNCT00189280Phase 3
Sponsor listed in the registry: MEDA Pharma GmbH & Co. KG · First submitted before MEDA Pharma GmbH & Co. KG became part of Viatris Inc.
- Relative Potency of Formoterol Novolizer® 12 µg Compared to Formoterol Aerolizer® 12 µgCompletedNCT01256086Phase 2
Sponsor listed in the registry: MEDA Pharma GmbH & Co. KG · First submitted before MEDA Pharma GmbH & Co. KG became part of Viatris Inc.
- 5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic DermatitisCompletedNCT00120523Phase 3
Sponsor listed in the registry: MEDA Pharma GmbH & Co. KG · First submitted before MEDA Pharma GmbH & Co. KG became part of Viatris Inc.
- Evaluation of Two Different Non-invasive Techniques to Monitor the Clearance of Actinic Keratosis LesionsCompletedNCT00294320Phase 3
Sponsor listed in the registry: MEDA Pharma GmbH & Co. KG · First submitted before MEDA Pharma GmbH & Co. KG became part of Viatris Inc.
- Long-term Effects of Imiquimod and Diclofenac in Actinic KeratosesCompletedNCT00777127Phase 4
Sponsor listed in the registry: MEDA Pharma GmbH & Co. KG · First submitted before MEDA Pharma GmbH & Co. KG became part of Viatris Inc.
- Comparative Study of Flecainide CR and Placebo in the Early Treatment of Atrial Fibrillation.TerminatedNCT00408473Phase 4
Sponsor listed in the registry: MEDA Pharma GmbH & Co. KG · First submitted before MEDA Pharma GmbH & Co. KG became part of Viatris Inc.
- Tepilta® Versus Oxetacaine, Antacids and PlaceboTerminatedNCT01336530Phase 3
Sponsor listed in the registry: MEDA Pharma GmbH & Co. KG · First submitted before MEDA Pharma GmbH & Co. KG became part of Viatris Inc.
- To Assess the Protective Effect of the Fixed Drug Combination of Disodium Cromoglycate Plus ReproterolCompletedNCT00777348Phase 2
Sponsor listed in the registry: MEDA Pharma GmbH & Co. KG · First submitted before MEDA Pharma GmbH & Co. KG became part of Viatris Inc.
- A Study to Evaluate the Effectiveness and Safety of Multiple Applications of Imiquimod 5% Cream for the Treatment of Actinic Keratoses in Organ Transplant RecipientsCompletedNCT00189267Phase 2
Sponsor listed in the registry: MEDA Pharma GmbH & Co. KG · First submitted before MEDA Pharma GmbH & Co. KG became part of Viatris Inc.
- Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2)CompletedNCT00328601Phase 3
Sponsor listed in the registry: MEDA Pharma GmbH & Co. KG · First submitted before MEDA Pharma GmbH & Co. KG became part of Viatris Inc.
- A Study to Evaluate Effectiveness of Imiquimod 5% Cream in Superficial Basal Cell CarcinomaCompletedNCT00189241Phase 3
Sponsor listed in the registry: MEDA Pharma GmbH & Co. KG · First submitted before MEDA Pharma GmbH & Co. KG became part of Viatris Inc.
- Single Dose Pharmacokinetics of Intranasal Fluticasone Delivered by a Fixed Combination With Azelastine (MP29 02) in Comparison to Two Different Fluticasone Nasal SpraysCompletedNCT01194622Phase 1
Sponsor listed in the registry: MEDA Pharma GmbH & Co. KG · First submitted before MEDA Pharma GmbH & Co. KG became part of Viatris Inc.
- To Evaluate the Impact of Oral Flecainide on Quality of Life in Patients With Paroxysmal Atrial FibrillationCompletedNCT00189319Phase 4
Sponsor listed in the registry: MEDA Pharma GmbH & Co. KG · First submitted before MEDA Pharma GmbH & Co. KG became part of Viatris Inc.
- Single Dose Pharmacokinetics of Intranasal Azelastine Delivered by a Fixed Combination With Fluticasone in Comparison to Azelastine Nasal SpraysCompletedNCT01190852Phase 1
Sponsor listed in the registry: MEDA Pharma GmbH & Co. KG · First submitted before MEDA Pharma GmbH & Co. KG became part of Viatris Inc.
- Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses (LEIDA 2)CompletedNCT01453179Phase 4
Sponsor listed in the registry: MEDA Pharma GmbH & Co. KG · First submitted before MEDA Pharma GmbH & Co. KG became part of Viatris Inc.
- Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital WartsCompletedNCT00189293Phase 4
Sponsor listed in the registry: MEDA Pharma GmbH & Co. KG · First submitted before MEDA Pharma GmbH & Co. KG became part of Viatris Inc.
- Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Diabetic Polyneuropathy (Stage 1 or 2)CompletedNCT00977483Phase 3
Sponsor listed in the registry: MEDA Pharma GmbH & Co. KG · First submitted before MEDA Pharma GmbH & Co. KG became part of Viatris Inc.
- Imiquimod 5% Cream in the Treatment of External Genital or Perianal Warts in HIV+ PatientsCompletedNCT00761371Phase 4
Sponsor listed in the registry: MEDA Pharma GmbH & Co. KG · First submitted before MEDA Pharma GmbH & Co. KG became part of Viatris Inc.
- A Study to Follow up Recurrence Rates of Actinic Keratoses One Year After Completion of Study 1487-IMIQCompletedNCT00189254
Sponsor listed in the registry: MEDA Pharma GmbH & Co. KG · First submitted before MEDA Pharma GmbH & Co. KG became part of Viatris Inc.